Abstract: A 41-year-old male presented with plaque psoriasis complicated by HIV/AIDS for 9 years. The patient received ulinumab and secuchiumab successively, and the effect was poor. The patient has been treated with guselkumab since 2019, and was diagnosed with hepatitis C in 2023, and liver function returned to normal after the treatment with sofosbuvir vipatavir. The patient was followed up for 4 years and the skin lesions completely subsided after mild recurrence, PASI, BSA, DLQI scores significantly improved. Laboratory tests showed that CD4+ T cell count increased from 405 cells /μL to 702 cells /μL, HIV RNA negative, and no significant adverse effects were observed. This case suggests that goucegiumab combined with highly active antiretroviral therapy (HAART) is safe and effective in patients with psoriasis complicated with HIV and hepatitis C, but further clinical trials are needed to verify its long-term efficacy and safety.

Key words: plaque psoriasis, guselkumab, AIDS